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Asbestos-Related Pleural Diseases: 




Several pleural diseases have been associated with asbestos exposure. Asbestos 
exposure may lead to the development of benign pleural diseases, such as pleural 
plaques, diffuse pleural thickening, and pleural effusion, as well as to the devel-
opment of malignant mesothelioma, a highly aggressive tumour of the pleura. 
Asbestos exposure related to pleural diseases may be occupational or environmen-
tal. Although the causal relationship between asbestos-related pleural diseases 
and asbestos exposure has been well confirmed, the role of genetic factors in the 
development of these diseases needs to be further investigated and elucidated. The 
results of the studies performed so far indicate that in addition to asbestos exposure, 
genetic factors as well as the interactions between genetic factors and asbestos 
exposure may have an important impact on the risk of asbestos-related pleural 
diseases, especially malignant mesothelioma. This chapter aims to present how the 
risk of developing asbestos-related pleural diseases may be influenced by asbestos 
exposure, genetic factors, interactions between different genetic factors, as well as 
interactions between different genetic factors and asbestos exposure.
Keywords: pleural plaques, malignant mesothelioma, asbestos exposure, genetic 
factors
1. Introduction
Asbestos-related diseases still represent an important health problem and a huge 
economic burden for the society all over the world. Asbestos exposure has been asso-
ciated with the development of asbestosis, pleural plaques, diffuse pleural thickening 
and pleural effusion, lung cancer, malignant mesothelioma of pleura and peritoneum, 
and several other types of cancers, like laryngeal cancer, ovarian cancer, as well as 
cancers of the buccal mucosa, pharynx, gastrointestinal tract, and kidney [1–13].
Asbestos-related diseases, including those of the pleura, are known to be among 
the most investigated occupational diseases [8–14].
2. Asbestos-related pleural diseases
Development of several pleural diseases has been associated with occupational or 
environmental asbestos exposure. Among them are pleural plaques, diffuse pleural 




Pleural plaques are benign (nonmalignant) pleural abnormalities and among the 
most common asbestos-related diseases [15–17].
Pleural plaques have been defined as circumscribed, quadrangular, irregular 
pleural elevations with clearly demarcated edges that are often bilateral and rarely 
symmetrical. They may enlarge and become calcified over time. Pleural plaques 
commonly develop in the lower two thirds of the thorax and mostly on the outer 
two thirds of diaphragm. They rarely occur within less than 20 years from the first 
exposure to asbestos [3, 5, 15–19].
Pleural plaques are mostly asymptomatic and may cause a slight impairment of 
lung function when they grow in size [20].
Small pleural plaques are often difficult to discern, and standard chest radio-
graphs are generally suboptimal for the visualisation of pleura, particularly in obese 
patients [3]. High-resolution CT (HRCT) scans are far superior to any other method 
for imaging pleural plaques as well as the diffuse pleural thickening [3, 21].
Pleural plaques have been referred predominately as a marker of asbestos 
exposure [2, 5, 22, 23] rather than an independent risk factor for malignant meso-
thelioma and lung cancer [2, 5, 24]. However, according to some authors, pleural 
plaques may also indicate an increased risk of asbestosis and asbestos-related 
cancers [18, 19]. Many studies have investigated the relationship between pleural 
plaques and lung cancer as well as between pleural plaques and malignant mesothe-
lioma; however, the results of these studies are not consistent [5, 24].
Regarding the relation between pleural plaques and malignant mesothelioma, 
Hillerdal et al. reported that pleural plaques on the chest roentgenogram indicate 
an increased risk for mesothelioma [25]. In their study Karjalainen et al. presented 
more than five times higher risk of malignant mesothelioma in asbestos-exposed 
men with benign pleural disease [26]. A statistically significant association between 
pleural plaques and malignant mesothelioma (unadjusted), and after adjustment 
for the time since the first exposure and the cumulative exposure index to asbestos, 
was observed also in the study of Pairon et al. Based on these results, Pairon et al. 
concluded that the presence of pleural plaques may be an independent risk factor 
for pleural mesothelioma [27]. On the other hand, Reid et al. reported no increased 
risk of pleural malignant mesothelioma in subjects with pleural thickening after 
adjustment for the time since the first exposure (log years), cumulative exposure 
(log f/ml-years), and age at the start of the programme; however, there was an 
increased risk of peritoneal mesothelioma [28].
Considering lung cancer, Fletcher reported two times higher risk of develop-
ing this malignoma in shipyard workers with pleural plaques compared to those 
without plaques [29]. Hillerdal et al. suggested that the risk for bronchial carcinoma 
may be increased in subjects with pleural plaques observed on the chest roentgeno-
gram [25]. A slightly elevated risk of lung cancer was found in the asbestos-exposed 
men with benign pleural disease also in the study of Karjalainen et al. [26]. In the 
study of Cullen et al., asbestos-exposed smokers with pleural plaques or other 
asbestos-related pleural changes had a 44% higher risk of lung cancer than the 
unexposed heavy smokers [30]. Lung cancer mortality was significantly associated 
with pleural plaques when unadjusted and also after adjustment for smoking and 
asbestos cumulative exposure index in the follow-up study of Pairon et al. They con-
cluded that pleural plaques may be an independent risk factor for lung cancer death 
in asbestos-exposed workers and could be used as an additional criterion in the 
definition of high-risk populations eligible for CT screening [27]. On the contrary, 
the study of Partanen et al. showed no increased risk of lung cancer in subjects with 
pleural plaques [31].
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Nevertheless, although pleural plaques may be the endpoint and the develop-
ment of pleural plaques may be an entirely independent process from the develop-
ment of malignant mesothelioma and lung cancer, it is likely there is a link between 
pleural plaques and the aforementioned malignant diseases [5].
2.2 Diffuse pleural thickening
Diffuse pleural thickening that affects visceral pleural surface is not sharply 
demarcated and is often associated with fibrous strands extending into the paren-
chyma. There are frequent adhesions between the visceral and parietal pleurae, 
leading to obliteration of the pleural space. It can be extensive and cover the whole 
lobe or even the whole lung. The thickness ranges from less than 1 mm up to 1 cm or 
more. Diffuse pleural thickening is a less frequent manifestation of asbestos expo-
sure than pleural plaques [15, 32–34].
Diffuse pleural thickening may lead to significant respiratory disability. In 
subjects with diffuse pleural thickening, forced vital capacity and single breath 
diffusing capacity are considered to be lower in comparison to subjects without this 
disorder [35–37].
From the diagnostic point of view, a chest radiograph is used as a standard 
method for detecting diffuse pleural thickenings; however, also in this case, HRCT 
scans are far superior to any other method [20, 37, 38].
Similar to pleural plaques, the diffuse pleural thickenings may be also associated 
with malignant diseases [20].
2.3 Pleural effusion
Asbestos-related changes of pleura include also benign asbestos pleural effusion, 
which is a nonmalignant pleural disease [39]. It has been first described in 1964, 
and it is also known as asbestos pleurisy [39, 40].
Diagnostic criteria for asbestos pleural effusion include previous asbestos 
exposure, determination of pleural effusion by chest radiograph, HRCT or thora-
cocentesis, and the absence of other causes of effusion [39]. In the vast majority of 
undiagnosed unilateral pleural effusions, the fluid is sent for cytological analysis. 
However, there still remains an uncertainty about the sensitivity to diagnose 
malignant pleural effusion. It is important to know that in patients presenting with 
clinical suspicion of malignant mesothelioma, cytological sensitivity is low [41].
Nevertheless, unexplained pleural effusion and pleural pain in subjects exposed 
to asbestos should always raise the suspicion of pleural malignant mesothelioma 
[42]. Sneddon et al. reported that more than 70% of patients with malignant 
mesothelioma develop pleural effusions, which contain tumour cells, representing a 
readily accessible source of malignant cells for genetic analysis [43].
2.4 Malignant mesothelioma
Malignant mesothelioma is a rare but highly aggressive and fatal cancer of 
serosal surfaces with poor prognosis, related to occupational and/or environmental 
(nonoccupational) asbestos exposure. It arises most commonly from mesothelium 
of the pleural surface. Rarely, it may occur also in other serosal membranes of the 
human body that are also coated with mesothelium, such as peritoneum, pericar-
dium, and tunica vaginalis [44–46].
The major cause and carcinogen for the development of malignant mesothe-
lioma is asbestos. In the study of McDonald et al., asbestos exposure was proved 
in almost 80% of patients with malignant mesothelioma [47]. Additionally in 
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the study of Franko et al., asbestos exposure was confirmed in 86% of patients 
with malignant mesothelioma, but it could not be confirmed with certainty in the 
remainder of the patients [48].
The latency period between the first exposure to asbestos and the development 
of malignant mesothelioma is long and can range from 15 to 60 years or even 
more [48–50].
Considering clinical features, in the vast majority of patients, the onset of 
symptoms is insidious and nonspecific, with chest pain and breathlessness being 
the most common features [51]. These symptoms are usually mild at the onset 
of the disease and are often attributed to other causes, which delays the diagno-
sis. The chest pain is often described as a sensation of heaviness or coldness in 
one side of chest or abdomen and can be caused by the effusion or the tumour 
[51–53]. The referral of this unspecified pain to the upper abdomen or shoulders, 
probably as a result of involvement of the diaphragmatic pleura, may lead to the 
inappropriate investigation and consequently delays the diagnosis. Breathlessness 
may be manifested as the new onset of dyspnoea or the deterioration of the symp-
toms of other respiratory diseases such as chronic obstructive pulmonary disease. 
The latter results in further diagnostic delays [51, 54]. Another feature during 
the course of this cancer is a dry cough, which is rarely troublesome in the early 
stages and is seen in about 10% of patients [51, 55]. Other relatively common 
features are weight loss, fatigue, anorexia, sweats, malaise, lassitude, and inter-
mittent low-grade fever [51, 56]. Malignant mesothelioma is occasionally found 
incidentally during radiological investigation of some other health problems. 
Another rather rare presentation of this malignoma is pneumothorax [51].
The most common form of spread of malignant mesothelioma in addition to the 
worsening of the presenting symptoms is dysphagia due to esophageal compres-
sion, sympathetic nerve involvement of the arm, neurological syndromes such as 
Horners’s syndrome, recurrent laryngeal nerve palsy, paraplegia as a result of spinal 
canal invasion, severe pain in the chest wall as a consequence of tumour invasion 
and nerve root involvement, malignant pericardial invasion and effusion, obstruc-
tion of superior venal cava, and occurrence of intermittent hypoglycemia [51, 53].
A rapid and accurate diagnosis of malignant mesothelioma is very important for 
therapeutic reasons [44]. Pleural pain and unexplained pleural effusion in subjects 
exposed to asbestos should raise the suspicion of pleural malignant mesothelioma. 
Chest radiography, which is a simple and easily available tool, is usually the first 
investigation performed. The typical findings are pleural effusion, occasionally 
nodular pleural thickening, irregular fissural thickening, or a localised mass lesion 
[57]. Important imaging modality is HRCT scanning, which at the diagnosis often 
shows pleural effusion at disease site, pleural thickening, as well as involvement of 
the interlobar fissure and invasion of the chest wall. As for MRI, it has superior soft 
tissue contrast over CT. Diffusion-weighted MRI is considered to be a promising 
strategy for evaluating tumour extension and response to treatment [57]. Another 
method is PET-CT, which combines HRCT scanning with injection of 18-fluoro-
deoxy-glucose; however, also this scan has several limitations as it cannot differenti-
ate between pleural malignant mesothelioma and metastatic pleural malignancy [57].
Invasive procedures are needed for prompt and accurate diagnosis of pleural 
malignant mesothelioma. Cytological samples are obtained by thoracentesis and 
biological tissue by ultrasound-/or radiological-guided biopsy or thoracoscopy [57]. 
Based on histopathology, malignant mesotheliomas can be classified into epithelioid, 
biphasic, and sarcomatoid subtypes [45]. However, this aggressive cancer remains dif-
ficult to diagnose in the early phases of the disease. Therefore, potential serum mark-
ers that could facilitate an early diagnosis and help to evaluate response to treatment 
have been extensively investigated. Among them are mesothelin [48, 58–60], fibulin-3 
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[61, 62], osteopontin [51], survivin [63], and others. However, the results of the stud-
ies on tumour markers are not consistent; therefore further research is needed.
Pleural malignant mesothelioma is treated by surgery, also used in combination 
with chemotherapy and/or radiotherapy, which attempts to eradicate the malignant 
tissue and is an essential option to help the patient to reduce the pain and control 
pleural effusions [46, 53]. Radiotherapy is relatively common treatment for pleural 
malignant mesothelioma. Although several studies have indicated that radiotherapy 
is unable to cure this cancer, it has been shown that radiotherapy administrated pre- 
or postoperatively alone or in combination with other treatments, is useful to limit 
tumour spreading, controls pain, and improves the 2-year rate of overall survival 
from 20 to 34% [46, 64]. However, the systemic cytotoxic chemotherapy remains 
one of the few therapeutic options that has been shown to improve survival in 
patients with malignant pleural mesothelioma even in advance stage, when patients 
are not candidates for aggressive surgery [46, 65]. The most commonly used is 
the combination of pemetrexed with cisplatin and gemcitabine with cisplatin or 
another platinum compound. It was reported that the combination of cisplatin 
and pemetrexed gave a 3-month survival benefit over cisplatin alone, improving 
median survival from 9.3 to 12.1 months [66]. Comparable results were obtained for 
gemcitabine/cisplatin doublet [67–70]. Furthermore, the introduction of chemo-
therapy, in particular treatment with low-dose gemcitabine in prolonged infusion 
and cisplatin significantly improved survival of Slovenian malignant mesothelioma 
patients with median overall survival being increased from 5.6 to 14.5 months [68].
3. Asbestos exposure and pleural diseases
Asbestos is a commercial collective name for a group of naturally occurring fibrous 
hydrated silicates that share similar physical and chemical properties [13, 71–75]. 
According to their fibre morphology, asbestos fibres have been sub-classified into 
two main groups, serpentine and amphibole. Serpentine asbestos includes chrysotile, 
which is also known as white asbestos. The vast category of amphiboles includes com-
mercial asbestos crocidolite (also named blue asbestos), amosite (also called brown 
asbestos), anthophyllite, as well as the noncommercial types of asbestos like actinolite 
and tremolite asbestos [13, 75–80].
These fibres have been greatly valued for their tensile strength, thermal resis-
tance, durability, and flexibility. However, on the other hand, asbestos fibres are 
known to cause inflammation, fibrotic changes in the lung, and malignant diseases 
[71, 72, 75].
Asbestos exposure related to asbestos-related pleural diseases, as well as to other 
asbestos-related diseases, may be occupational or/and environmental.
Workers may be occupationally exposed to asbestos in many working sectors, 
including disposal of asbestos waste and materials; construction; asbestos-cement 
industry; brickworks; asphalt mixing; machine and insulation products industry; 
production of clutches and brakes; bus, lorry, railway carriage, car, and airplane 
repair; ship repair and building; textile industry; asbestos mining, production and 
milling of asbestos fibres; textile industry; and other sectors [73–75, 77, 81–83].
Environmental (nonoccupational) exposure to asbestos (in the neighbourhood 
or household) occurs in the vicinity of the factories and other working sectors 
where asbestos is used. In these areas inhabitants are exposed to asbestos with pol-
luted air, water, and food. Nonoccupational exposure to asbestos may also occur due 
to the use and improper removal of asbestos-cement roofing, asbestos insulation, 
and other products containing asbestos. Asbestos fibres can be found in water that 
runs on asbestos-cement tubes, especially if they do not have lining or if they are 
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damaged. Family members of workers who work with asbestos and bring asbestos 
home with clothes, shoes, and hair can also be exposed to asbestos [13, 81–83].
Although the causal relationship between asbestos-related pleural diseases and 
asbestos exposure has been well confirmed, the role of genetic factors in the devel-
opment of these diseases needs to be further investigated and elucidated.
3.1 Molecular mechanisms linking asbestos exposure and pleural diseases
Recent studies have led to a better understanding of molecular mechanisms 
underlying the pathogenesis of asbestos-related diseases, including malignant 
mesothelioma. Although it has been shown that asbestos fibres deposited in lungs 
and translocated to pleura may have direct genotoxic effects on epithelial and 
mesothelial cells, the main molecular mechanism linking asbestos exposure with 
fibroplasia and neoplasia is related to the generation of reactive oxygen and nitric 
species thus leading to oxidative stress and inflammation [84].
Reactive oxygen species (ROS) such as hydrogen peroxide (H2O2), superoxide 
anion (O2 
−), hydroxyl radical (OH•), and reactive nitrogen species (RNS) can be 
generated directly by the asbestos fibres as they contain redox-active iron (Fe2+, 
Fe3+) that may catalyse the formation of hydroxyl radical through Fenton reaction 
[85]. Secondly, ROS may be generated also indirectly by inflammatory cells such 
as macrophages during the frustrated phagocytosis of asbestos fibres. This process 
also leads to the release of proinflammatory cytokines that further potentiate the 
asbestos-related inflammatory response [86].
Another recently described molecular mechanism by which asbestos may 
contribute to inflammation is the activation of the so-called pattern recognition 
receptors that sense pathogen-associated or damage-associated molecular pat-
terns (PAMPs or DAMPs, respectively) and trigger cellular responses. One class of 
these receptors, the nucleotide binding and oligomerization domain (NOD)-like 
receptors (NLRs), has been shown to be directly activated by asbestos fibres [87]. 
NLRP3 inflammasomes may be activated also indirectly by the released ROS and 
proinflammatory cytokines such as high-mobility group box 1 protein (HMGB1) 
[88]. Activation of NLR triggers assembly and activation of a multiprotein 
complex composed of the NLRP3 scaffold protein, CARD containing adaptor 
protein, and caspase-1. The subsequent cleavage and activation of caspase-1 
lead to the downstream cleavage of pro-interleukin-1β (pro-IL-1β) and release 
of mature proinflammatory cytokine IL-1β that triggers the early inflammatory 
response following asbestos exposure [89]. IL-1β release then leads to activation 
and enhanced expression of other cytokines, among them tumour necrosis factor 
(TNF) and transforming growth factor beta-1 (TGFB1) [90, 91]. Furthermore, 
TGFB1 may downregulate collagen degradation through matrix metallopro-
teinases (MMPs) and their inhibitors (TIMPs). Several MMPs and TIMPs play 
an essential role in tissue repair and remodelling. Among them, MMP1, MMP9, 
MMP12, and TIMP2 have been proposed to contribute to the development of 
pulmonary fibrosis [92].
Asbestos fibres and ROS may also activate other receptors and signalling path-
ways such as epidermal growth factor receptor (EGFR) and the downstream protein 
kinases AKT and ERK, leading to the activation of c-Fos and c-Jun proto-oncogenes 
and dysregulation of mitogenic signalling, promoting fibrosis and malignant 
transformation [93]. Because of the long-term persistence of asbestos fibres, the 
inflammation becomes chronic and is accompanied by gradual progression from 
mesothelial hyperplasia to mesothelioma after a latency period of several decades. 
In vitro and in vivo evidence implicate oxidative stress, chronic inflammation, 
genetic and epigenetic alterations, as well as direct cellular toxicity and genotoxicity 
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as the main mechanisms in the asbestos-related development of fibrosis and in 
malignant mesothelial cell transformation [94].
Numerous chromosomal abnormalities and genetic and epigenetic alterations 
were identified in human mesothelioma tissues in asbestos-exposed workers [94]. 
Asbestos-induced mutagenicity is also mediated through direct or indirect path-
ways. Asbestos fibres may induce mutagenicity and genotoxicity directly through 
physical interaction with the mitotic machinery of dividing cells after being phago-
cytized by the target cells. Longer asbestos fibres in particular, may cause DNA 
double-strand breaks or interact with the mitotic spindle thus leading to aneuploidy 
[94]. The indirect genotoxic and mutagenic effects occur due to asbestos-generated 
ROS and RNS that may produce a variety of DNA and chromosomal damages, 
such as 8-hydroxydeoxyguanosine (8-OHdG), DNA single-strand breaks, and 
chromosome fragmentation. Other frequently observed genomic alteration includes 
homozygous deletion or change of methylation pattern of tumour suppressor and 
p16INK4a and p14ARF at the 9p21 locus in humans. p16INK4a/p14ARF homozygous 
deletion has been reported to occur at a frequency of 50–70% of MM tissues and 
primary MM cells, whereas in stable MM cell lines, the frequency is as high as 90%. 
The loss of p16INK4a/p14ARF leads to the inactivation of another two important 
tumour suppressors, pRB and p53. The loss of neurofibromatosis type 2 (NF2) gene 
leads to the deficiency of its product Merlin and the consequent loss of inhibition of 
Merlin’s downstream target YAP, a proto-oncogene and transcriptional coactivator 
that promotes cell proliferation. Copy number amplification of proto-oncogenes 
such as JUN, MYC, and YAP was also reported [94].
Homozygous deletion of another tumour suppressor gene, BAP1, was recently 
reported in familial malignant mesothelioma. BAP1 is part of a multiprotein complex 
that is involved in DNA damage response and regulation of gene transcription [95].
3.2  The role of genetic factors in the development of asbestos-related pleural 
diseases
Recent studies have shown that in addition to asbestos exposure, genetic factors 
may have an important role in the occurrence, progression, and response to treat-
ment of asbestos-related diseases. Most studies have focused on genetic variability, 
in particular genetic polymorphisms in genes involved in the pathways related to 
molecular mechanisms linking asbestos exposure and pleural diseases as potential 
candidate genes that may influence individual susceptibility to asbestos-associated 
disorders. Most of the studies focused on asbestosis and malignant mesothelioma 
as the most common respective nonmalignant and malignant diseases related to 
asbestos exposure, while only a small number of studies included patients with 
pleural thickening and pleural plaques. This chapter is leaving asbestosis-related 
studies aside, as they are related to interstitial and not pleural lung disease.
3.2.1 Genetic variability in antioxidative defence genes
The defence mechanism against ROS is complex and involves several enzymes. 
Superoxide dismutases (SODs), catalase (CAT), and glutathione peroxidases (GPX) 
constitute the first line of the antioxidant enzyme defence system against ROS, 
while glutathione S-transferases (GSTs) play an important role in the detoxification 
of cytotoxic secondary metabolites of ROS. The major GST enzyme in the human 
lung is GSTP1, which belongs to the Pi class. Two other important polymorphic 
GSTs are GSTM1 (Mu class) and GSTT1 (Theta class) [96]. Another Phase 2 
enzyme studied in asbestos-related diseases is N-acetyltransferase 2 (NAT2), 
involved in the metabolism of various xenobiotics including the aromatic and 
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heterocyclic amines present in tobacco smoke and the diet [97]. The genes coding 
for all these enzymes are known to be polymorphic. Some of these polymorphisms 
alter gene expression or enzymatic activity and may modify the ability for the elimi-
nation of ROS or their products [98–100].
Manganese SOD (SOD2) was found to be highly expressed in malignant meso-
thelioma; however, SOD2 rs1799725 (Val16Ala) polymorphism was not found to 
be associated with either malignant or nonmalignant asbestos-related diseases in 
a group of 124 Finnish asbestos insulators, among which 20 workers developed 
malignant mesothelioma, 41 had nonmalignant pulmonary disorders such as 
asbestosis and/or pleural plaques, while 63 had no pulmonary disorders [98]. On 
the other hand, homozygotes for SOD2 16Ala/Ala genotype were found to have a 
threefold increased risk for malignant mesothelioma when genotype distributions 
were compared among 90 Italian patients with malignant mesothelioma and 395 
controls [100]. In this cohort, increased risk for malignant mesothelioma was also 
observed in carriers of homozygous GSTM1 deletion (GSTM1 null genotype), while 
no association was observed for polymorphisms in other GST genes [100].
Kukkonen et al. [101] investigated nine polymorphisms in six genes (EPHX1, 
GSTM1, GSTM3, GSTP1, GSTT1, and NAT2) related to metabolism of oxidative 
species in a cohort of 1008 Finnish asbestos-exposed workers. Only a trend of 
association was observed between GSTM1 null genotype and the extent of pleural 
plaques as well as between GSTP1 Ile105Val polymorphism and the calcification 
of pleural plaques. However, when pleural plaques were stratified according to the 
severity of radiological changes, GSTT1 null genotype was significantly associated 
with the greatest thickness of the pleural plaques [101].
No association was also found between SOD2 and CAT polymorphisms and 
the malignant mesothelioma risk in a study that included 159 Slovenian malignant 
mesothelioma patients and 122 controls. All the controls were occupationally 
exposed to asbestos in the asbestos-cement manufacturing plant but did not 
develop any disease associated with asbestos exposure [102]. However, this study 
reported an association between NAD(P)H quinone dehydrogenase 1 (NQO1) 
rs1800566 (p.Pro187Ser) SNP and malignant mesothelioma risk. NQO1 catalyses 
the reduction of quinones to hydroquinones, thus preventing the formation of free 
radicals. The carriers of at least one polymorphic NQO1 allele (CT and TT geno-
types) had an increased risk of malignant mesothelioma compared to carriers of 
homozygous wild-type CC genotype [102].
In a Finnish cohort, an association was reported between the NAT2 slow-
acetylator genotype and increased risk for both malignant (mesothelioma) and 
nonmalignant (asbestosis and pleural plaques) pulmonary disorders among 
asbestos-exposed workers [103, 104]. On the contrary, the NAT2 slow-acetylator 
genotypes were associated with decreased risk of mesothelioma in the Italian study 
population [105]. Conflicting results were reported also regarding the impact of 
microsomal epoxide hydrolase (EPHX1), a metabolising enzyme that plays a dual 
role in the activation and detoxification of exogenous chemicals, such as epoxides 
and PAHs [106]. EPHX1 low-activity genotypes were positively associated with 
malignant mesothelioma in the Italian study population, while in the Finnish study 
population, the association was negative [105].
3.2.2 Genetic variability in NLRP3 inflammasome
Two polymorphic genes leading to enhanced innate immune response and 
increased production of inflammatory cytokines were investigated in asbestos-
related pleural diseases. NLRP3 rs35829419 (p.Gln705Lys; C > A) is a gain-of-
function polymorphism that leads to increased NLRP3 activation after stimulation. 
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On the other hand, CARD8 rs2043211 (p.Cys10Ter, A > T) is a loss of function SNP 
that results in nonfunctional protein so that the CARD-8 inhibition of caspase-1 is 
lost. Therefore, both SNPs are associated with proinflammatory phenotype [107, 
108]. Both SNPs were analysed in a large Finnish study that investigated 16 poly-
morphisms from nine genes (NLRP3, CARD8, TNF, TGFB1, GC, MMP1, MMP9, 
MMP12, and TIMP2) involved in innate immunity and intracellular matrix remod-
elling in 951 Finnish asbestos-exposed workers. Among the two investigated NLRP3 
SNPs, only rs35829419 was associated with interstitial lung fibrosis but showed no 
association with fibrotic changes of pleura. Among the three investigated CARD8 
SNPs, rs2043211 (p.Cys10Ter, A > T) was associated with the greatest thickness of 
pleural plaques [107].
3.2.3 Genetic variability in signalling and inflammatory pathways
Asbestos-related activation of inflammation also leads to increased TNF and 
TGFB1 production. TNF promoter polymorphism rs1800629 (−308G > A) was 
reported to lead to higher constitutive and inducible transcriptional TNFa levels 
[109]. Genotype and allele frequencies of TNF promoter polymorphism rs1800629 
(−308G > A) were associated with radiographic pleural changes among German 
workers occupationally exposed to asbestos. Compared with the healthy nonex-
posed control group, carriers of at least one polymorphic TNF −308 A allele had 
at higher risk for hyaline pleural plaques, while no association was observed for 
calcified pleural plaques [91].
TGFB1 is a multifunctional cytokine that regulates the proliferation and dif-
ferentiation of cells [110] and was reported to promote the pathogenesis of lung 
fibrosis and act as a tumour suppressor in normal cells. Two TGFB1 polymorphisms 
in codons 10 (Leu10Pro) and 25 (Arg25Pro) affecting TGFB1 protein production 
were associated with a higher risk for fibrotic lung diseases but a lower risk for lung 
cancer in a German cohort that included 591 patients with pulmonary fibrosis, 147 
patients with bronchial carcinoma, and 83 healthy control subjects [90].
Kukkonen et al. investigated common polymorphisms in TNF and TGFB1 genes; 
however, only TGFB1 showed associations with visceral pleural fibrosis among 
951 Finnish Caucasian asbestos-exposed workers. In stratified analysis carriers of 
at least one TGFB1 rs2241718 variant allele were protected against visceral pleural 
fibrosis. On the other hand, TGFB1 haplotype analysis showed an association with 
pleural plaque calcification. In particular, TGFB1 rs1800469-rs1800470 GC and AT 
haplotypes conferred increased risks for pleural plaque calcification when com-
pared with the most common haplotype, GT [107].
3.2.4 Genes involved in matrix remodelling
In the above-mentioned study, Kukkonen et al. also investigated common poly-
morphisms of several metalloproteinases and their inhibitors (MMP1 rs1799750, 
MMP9 rs3918242, MMP12 rs652438, and TIMP2 rs2277698) involved in matrix 
remodelling. The study reported an association between the TIMP2 rs2277698 SNP 
and pleural thickenings, and the variant allele was found to predispose to a high 
degree of pleural plaque calcification [107].
Strbac et al. investigated 10 different SNPs in three MMP genes (MMP2, MMP9, 
and MMP14) in a group of 236 Slovenian patients with malignant mesothelioma 
and 161 healthy blood donors as the control group. The study reported a decreased 
risk for malignant mesothelioma in carriers of at least one polymorphic MMP2 
rs243865 allele, and this association was even more pronounced in patients with 
known asbestos exposure. None of the other tested polymorphisms showed 
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association with the risk of malignant pleural mesothelioma [111]. Furthermore, 
a study including 199 Slovenian malignant mesothelioma patients suggested that 
MMP polymorphisms may have a role as prognostic biomarkers in malignant meso-
thelioma, as carriers of polymorphic MMP9 rs2250889 allele had shorter time to 
progression and shorter overall survival compared to noncarriers. In contrast, carri-
ers of at least one polymorphic MMP9 rs20544 allele had longer time to progression 
and longer OS (overall survival than noncarriers [112].
3.2.5 Genes involved in DNA repair mechanisms
It has been suggested that genetic variability of proteins involved in DNA 
repair mechanisms may affect the risk of malignant mesothelioma. Based on the 
mechanisms of either oxidative stress related or direct DNA damage discussed 
above, polymorphic genes in DNA repair pathways such as base excision repair 
(BER), nucleotide excision repair (NER), as well as homologous recombination may 
play a role in susceptibility to asbestos-related malignant diseases [93]. However, 
so far only a few studies investigated the influence of the genetic variability of 
proteins involved in DNA repair mechanisms on the development of malignant 
mesothelioma. In particular, polymorphisms in genes coding for excision repair 
cross-complementing group 1 protein (ERCC1) involved in NER and X-ray repair 
cross-complementing protein 1 (XRCC1) involved in BER were most frequently 
investigated in asbestos-related malignant diseases [113, 114].
Dianzani et al. investigated seven SNPs in four DNA repair genes (XRCC1, 
XRCC3, XPD, and OGG1) in a population-based case-control study that included 81 
patients and 110 age and sex-matched controls from Casale Monferrato, an Italian 
town known for high levels of asbestos pollution. Two of the investigated polymor-
phisms were significantly associated with increased malignant mesothelioma risk in 
both homozygous and heterozygous carriers when compared to noncarriers: XRCC1 
rs25487 (399Q ) and XRCC3 rs861539 (241T). Homozygous and heterozygous 
carriers of OGG1 rs1052133 −326C allele were also at increased risk for malignant 
mesothelioma; but this association did not reach statistical significance. Also, the 
association with malignant mesothelioma risk was not significant when XRCC1 and 
XRCC3 haplotypes were considered [113].
A follow-up study included 220 malignant mesothelioma patients and 296 
controls from two Italian towns, Casale and Turin, and investigated 35 SNPs in 15 
genes possibly related to asbestos carcinogenicity. Among them, 14 SNPs in 10 genes 
involved in DNA repair were studied; however, only three SNPs were found to be 
associated with malignant mesothelioma. When only asbestos-exposed patients were 
considered in the analysis, the risk for malignant mesothelioma was found to increase 
with the number of XRCC1 rs25487 (399Q ) polymorphic alleles and XRCC1 −77T 
alleles. Increased risk for malignant mesothelioma was also observed in XRCC1 haplo-
type analysis. ERCC1 rs11615 (N118N) polymorphism was also found to be associated 
with increased malignant mesothelioma risk in the dominant genetic model, both in 
the entire study group and when considering only asbestos-exposed patients [114].
Betti et al. also investigated one functional SNP in hOGG (rs1052133 
p.Ser326Cys) involved in the repair of 8-oxoguanine that may result from ROS 
damage; however no association was found with the risk for malignant mesothe-
lioma [114]. Similarly, no association between this polymorphism and the risk for 
malignant mesothelioma was observed in a Slovenian study cohort of 150 malignant 
mesothelioma patients and 122 controls, who were occupationally exposed to 
asbestos but did not develop any asbestos-related diseases [102].
Recently, a larger number of 273 malignant mesothelioma patients and 193 
controls from the same Slovenian cohort were analysed for four SNPs in two DNA 
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repair genes (ERCC1 rs11615, rs3212986, and XRCC1 rs1799782, rs25487), but only 
ERCC1 rs3212986 was found to be significantly associated with the risk for malig-
nant mesothelioma. However, this polymorphism was found to have a protective 
effect as carriers of ERCC1 rs3212986 heterozygous GT or homozygous TT geno-
types had a decreased risk of malignant mesothelioma [115].
4. Gene-environment interactions in asbestos-related pleural diseases
It has become increasingly obvious that both environmental and genetic factors 
may influence the development of many diseases [116–119], including asbestos-
related pleural diseases.
Therefore it is important to consider gene-environment interactions when 
studying diseases related to exposure to different hazards, such as asbestos. 
Environmental and lifestyle factors have been investigated in many epidemiological 
studies using self-reported information obtained by questionnaires, interviews, 
records, or measurements of exposure. However, very few epidemiological studies 
included the information on genetic risk factors. Similarly, many studies investi-
gating genetic factors obtained little information on environmental factors and 
lifestyle. Genetic predisposition can be presumed from family history, phenotypic 
characteristics (e.g., metabolic capacity), or, most importantly, the analysis of DNA 
sequence. The research into gene-environment interactions requires the informa-
tion on both environmental and genetic factors [116–118]. Primary candidates 
for the gene-environment interaction studies have been mostly genes coding for 
xenobiotic metabolising enzymes. Genetic variability in these genes may lead to 
interindividual differences in capacity for xenobiotics metabolism, thus modifying 
an individual’s susceptibility to the development of diseases [116]. Furthermore, 
genetic factors usually do not act independently but may also interact or modify 
each other. This applies also to asbestos-related pleural diseases [102].
The results of the studies performed so far indicate that in addition to asbestos 
exposure, the genetic factors, as well as the interactions between genetic factors and 
asbestos exposure, may have an important impact on the risk of asbestos-related 
pleural diseases, in particular on malignant mesothelioma [102, 115, 120, 121].
Regarding asbestos-related pleural diseases, the interactions between genetic fac-
tors and asbestos exposure have been studied in the case of malignant mesothelioma 
[102, 115, 120, 121].
The case-control study of Franko et al. investigated the influence of functional 
polymorphisms of NQO1, CAT, SOD2, and hOGG1 genes, gene-gene interactions, and 
gene-environment interactions on malignant mesothelioma risk. The authors reported 
that although there was no independent association between either CAT rs1001179 
or hOGG1 rs1052133 polymorphism and malignant mesothelioma, the interaction 
between both polymorphisms showed a protective effect. However, no interaction was 
found between investigated genetic polymorphisms and asbestos exposure [102].
The case-control study of Levpuscek et al. that investigated the influence of 
functional polymorphisms in ERCC1 and XRCC1 genes, the interactions between 
these polymorphisms, as well as the interactions between these polymorphisms 
and asbestos exposure on malignant mesothelioma risk found that interaction 
between ERCC1 rs11615 polymorphism and asbestos exposure significantly 
influenced the risk of this cancer. Carriers of polymorphic ERCC1 rs11615 allele 
who were exposed to the low level of asbestos had a decreased risk of malignant 
mesothelioma. Based on these findings, it has been suggested that the genetic 
variability of DNA repair mechanisms could contribute to the risk of developing of 
this aggressive cancer [115].
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The possible impact of gene-environment interactions on pleural malignant 
mesothelioma risk was investigated also in the study of Tunesi et al., who con-
ducted a gene-environment interaction analysis including asbestos exposure and 15 
single nucleotide polymorphisms (SNPs) previously identified through a genome-
wide association study on Italian subjects. Positive deviation from additivity was 
found for six SNPs (rs1508805, rs2501618, rs4701085, rs4290865, rs10519201, and 
rs763271), and four of them (rs1508805, rs2501618, rs4701085, and rs10519201) 
deviated also from multiplicative models. Generalised multifactor dimensional-
ity reduction analysis showed a strong malignant pleural mesothelioma risk due 
to asbestos exposure and suggested a possible synergistic effect between asbestos 
exposure and rs1508805, rs2501618, and rs5756444. The results of the presented 
study also suggested that gene-asbestos interaction may play an additional role in 
malignant pleural mesothelioma susceptibility [120].
According to our knowledge and the available literature, the influence of gene-
environment interactions on the risk of developing other asbestos-related diseases 
(pleural plaques, diffuse pleural thickening) has not been studied so far.
5. Conclusions
Given that asbestos is still present in the working and living environment all 
over the world and that pleural asbestos-related diseases, in particular malig-
nant mesothelioma, represent an important health problem worldwide, further 
research is needed to identify new serum and genetic and epigenetic markers 
of risk for developing these diseases, for early diagnosis, and for prediction of 
disease progression and response to treatment. The increasing incidence and 
poor prognosis of pleural malignant mesothelioma calls for new more effective 
detection methods, including the identification of novel biomarkers for early and 
reliable detection of this aggressive cancer, especially in high-risk populations 
with a known history of asbestos exposure. The influence of gene-environment 
interactions on the risk of these diseases may be particularly important and should 
be further investigated. These findings may serve as a basis for the development 
of new methods for an earlier diagnosis of asbestos-related pleural diseases and 
may also be used to identify new targets for a more effective treatment, especially 
of malignant mesothelioma. Furthermore, they could add to our understanding of 
pathogenesis of asbestos-related pleural diseases and enable their prevention. In 
this way, they could significantly contribute to the improvement of the quality of 
life as well as to prolonging lifespan and ageing of subjects exposed to asbestos.
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